Clinical Trial Update: PRostate Olaparib Real World Evidence Study

View source ↗

Summary

A real-world evidence study evaluating Olaparib for metastatic castration-resistant prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Lynparza (olaparib)

Snippet

Sponsor: AstraZeneca | Conditions: Metastatic Castration-resistant Prostate Cancer | Status: RECRUITING